From April 2 to 5, Cergentis attended the Bioprocessing International (BPI) Europe conference in Vienna, Austria.
We were pleased that amongst others, GSK, Boehringer Ingelheim and Amgen presented their work supported by our TLA technology in the Cell Line Development & Engineering stream and Vaccines stream of the conference.
Cergentis’ founding director Max van Min on the conference:
"Our attendance at BPI 2019 was very successful. We joined interesting presentations, welcomed a lot of visitors at the Cergentis booth to learn more about Targeted Locus Amplification and met with many of our loyal customers.”
During various panel discussions at BPI, TLA was described by key opinion leaders as the gold standard for enhanced genetic characterisation of cell lines. Without a doubt, this conference elegantly illustrated that both Cergentis and TLA are established and well-known for its essential and unique value in the (CHO) cell line development field.